Israeli biotech Ormed is developing oral medicines to treat conditions that normally require injections. Its flagship product, the ORMD-0801 insulin capsule for Type 1 (juvenile) diabetes has just successfully completed clinical trials. Ormed’s share price rose 115 percent on the news.
http://www.prnewswire.co.il/news-releases/oramed-announces-successful-results-from-ex-us-pharmacokinetic-study-of-its-oral-insulin-for-the-treatment-of-type-1-diabetes-236703681.html